Lithosun SR 400 mg Tab. 400mg

Tablet

Pack Size : 10 Tablet x 1 Strip

Generics : Lithium Carbonate

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 56.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Lithosun SR 400 mg Tab Sun Pharmaceutical (Bangladesh) Ltd.

Tk 5.60

More Information About - Lithosun SR 400 mg Tab. 400mg

Description

Generic Name

Lithium Carbonate

Precaution

Decreased tolerance to lithium has been reported to ensue from protracted sweating or diarrhoea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved. Lactation: Drug is excreted in breast milk; use not recommended

Indication

Bipolar disorder, Mania, Recurrent unipolar depression

Contra Indication

Renal insufficiency, cardiovascular insufficiency, Addison\'s disease and untreated hypothyroidism are all contraindications to lithium therapy.

Dose

N/A

Side Effect

>10% Leukocytosis (most patients),Polyuria/polydypsia (30-50%),Dry mouth (20-50%),Hand tremor (45% initially, 10% after 1 year of treatment),Confusion (40%),Decreased memory (40%),Headache (40%),Muscle weakness (30% initially, 1% after 1 year of treatment),Electrocardiographic (ECG) changes (20-30%),Nausea, vomiting, diarrhea (10-30% initially, 1-10% after 1-2 years of treatment),Hyperreflexia (15%),Muscle twitch (15%),Vertigo (15%) 1-10% Extrapyramidal symptoms, goiter (5%),Hypothyroidism (1-4%),Acne (1%),Hair thinning (1%) Frequency Not Defined Coma,Lethargy,Seizures,Renal toxicity

Pregnancy Category

Name : D

Description

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Mode of Action

Inhibits postsynaptic D2 receptor supersensitivity. Alters cation transport in nerve and muscle cells and influences reuptake of serotonin or norepinephrine. Inhibits phosphatidylinositol cycle second messenger systems.

Interaction

Reduced serum levels with carbonic anhydrase inhibitors, chlorpromazine, sodium-containing preparations, theophylline, urea. Enhanced hypothyroid effects with iodine salts. Enhanced effects of neuromuscular-blocking agents. Reduced pressor response to sympathomimetics. Potentially Fatal: Increased risk of lithium toxicity with ACE inhibitors, angiotensin receptor antagonists, loop diuretics, metronidazole, phenytoin. Increased risk of neurotoxicity with carbamazepine, calcium-channel blockers, haloperidol, methyldopa, phenothiazines, SSRIs, TCAs. Increased serum levels with COX-2 inhibitors, NSAIDs (except sulindac, aspirin), tetracyclines, thiazide diuretics. Increased risk of encephalopathy with haloperidol. Increased risk of serotonin syndrome with sibutramine. Fatal malignant hyperpyrexia may occur when used with MAOIs.

Pregnancy Category Note

N/A

Adult Dose

Oral Mania; Bipolar disorder; Recurrent unipolar depression Adult: Treatment and prevention: Initially, 400-1,200 mg daily in 1-2 divided doses. Serum lithium should be monitored 12 hours after dose, twice weekly until serum concentration and clinical condition stabilize, and every other month thereafter Desirable range for serum lithium: 0.6-1.2 mEq/L; although higher serum concentrations may be needed, not to exceed 1.5 mEq/L

Child Dose

N/A

Renal Dose

Renal impairment: CrCl (ml/min) Dosage Recommendation 10-50 50-75% of normal dose. <10 25-50% of normal dose.

Administration

Should be taken with food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.